Bruce Belzer, MD
Family Medicine · Boise, IDNPI 1083666382
Payments from drug & device makers
Across 178 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$414
- Amgen$381
- Pfizer$337
- Novo Nordisk$261
- AbbVie$223
- Boehringer Ingelheim$199
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,911100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $414 |
| Amgen | 19 | $381 |
| Pfizer | 32 | $337 |
| Novo Nordisk | 19 | $261 |
| AbbVie(2 entities) | 10 | $223 |
| Boehringer Ingelheim | 11 | $199 |
| GSK | 8 | $132 |
| Lilly USA, LLC | 9 | $123 |
| Teva Pharmaceuticals USA, Inc. | 6 | $81 |
| Exact Sciences | 4 | $72 |
| Merck | 4 | $66 |
| Dexcom, Inc. | 2 | $55 |
| Bayer | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Antares Pharma, Inc. | 3 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $37 |
| Johnson & Johnson | 3 | $35 |
| Genentech USA, Inc. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Dynavax Technologies Corporation | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Medtronic | 1 | $20 |
| Halozyme Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Novartis | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$2,914 in reported general payments places this provider in the 85th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 105 | $156,542 |
| EliquisApixaban | 91 | $129,610 |
| TrulicityDulaglutide | 88 | $123,984 |
| FarxigaDapagliflozin Propanediol | 58 | $74,595 |
| RybelsusSemaglutide | 35 | $59,564 |
| MounjaroTirzepatide | 43 | $58,586 |
| OzempicSemaglutide | 38 | $52,652 |
| XareltoRivaroxaban | 31 | $40,865 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $29,514 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $28,796 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $27,208 |
| JanuviaSitagliptin Phosphate | 16 | $24,055 |
| Testosterone | 34 | $20,958 |
| MyrbetriqMirabegron | 26 | $19,063 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $15,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $123 | $182,571131 claims |
| Boehringer IngelheimJardiance | $199 | $156,542105 claims |
| PfizerEliquis | $337 | $129,61091 claims |
| Novo NordiskRybelsus, Ozempic | $261 | $112,21673 claims |
| AstraZenecaFarxiga | $414 | $74,59558 claims |
| Johnson & JohnsonXarelto | $35 | $40,86531 claims |
| GSKTrelegy Ellipta | $132 | $29,51423 claims |
| MerckJanuvia | $66 | $24,05516 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $19,06326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 803 family medicine providers in Idaho.
Other family medicine in Boise
- Brock McConneheyBoise$4.5M
- Diane McConneheyBoise$681K
- Phyllis YouBoise$88K
- John EckBoise$55K
- Kara CadwalladerBoise$24K
- Cyrus VaniaBoise$9K
- Joshua AdamsBoise$8K
- Nicole StiversBoise$7K
- Ammon RobertsBoise$7K
- Mark TurnerMeridian$40.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.